Lutris Pharma’s LUT014 Gel Shows Promise in Treating Skin Rash from Cancer Therapies at ESMO 2025#Israel#Tel_Aviv#Lutris_Pharma#LUT014#EGFR_Therapies
Lutris Pharma’s LUT014 Gel Shows Promise in Treating Skin Rash from Cancer Therapies at ESMO 2025
Lutris Pharma presents encouraging results from a Phase 2 study of LUT014 Gel, demonstrating its effectiveness against acneiform rash from anti-EGFR therapies, enhancing patients' treatment adherence.
third-news.com
July 7, 2025 at 2:42 PM
Lutris Pharma’s LUT014 Gel Shows Promise in Treating Skin Rash from Cancer Therapies at ESMO 2025#Israel#Tel_Aviv#Lutris_Pharma#LUT014#EGFR_Therapies